FrancophonIA/ELRC3.0 huggingface dataset:
English: In one study 56% of patients given Zykadia (92 of 163) were considered by the treating doctors to have shown a complete or partial response to the medicine.
Maltese: Fi studju wieħed, 56 % tal-pazjenti li ngħataw Zykadia (92 minn 163) ġew ikkunsidrati mit-tobba li kkurawhom bħala li wrew rispons komplet jew parzjali għall-mediċina.
English: Zykadia was originally given ‘conditional approval' because there was more evidence to come about the medicine.
Maltese: Oriġinarjament Zykadia ngħata “approvazzjoni kondizzjonali” għax kien għad hemm iktar evidenza x'tingħata dwar il-mediċina.
English: What are the risks associated with Zykadia?
Maltese: X'inhuma r-riskji assoċjati ma' Zykadia?
English: As for all medicines, data on the use of Zykadia are continuously monitored.
Maltese: Bħal għall-mediċini kollha, id-data dwar l-użu ta' Zykadia hija ssorveljata kontinwament.
English: ALK belongs to a family of proteins called receptor tyrosine kinases, which are involved in the growth of cells and the development of new blood vessels that supply them.
Maltese: ALK tagħmel parti minn familja ta' proteini msejħa riċettur tat-tirożina kinasi (receptor tyrosine kinases), li huma involuti fit-tkabbir taċ-ċelloli u fl-iżvilupp ta' vażi ġodda li jfornuhom.
English: Zykadia is a cancer medicine used on its own to treat adults with a type of lung cancer called nonsmall-cell lung cancer (NSCLC), when the disease is advanced.
Maltese: Zykadia huwa mediċina kontra l-kanċer li jintuża waħdu fil-kura ta' adulti b'tip ta' kanċer tal-pulmun magħruf bħala kanċer tal-pulmun mhux taċ-ċelloli żgħar (NSCLC, non-small-cell lung cancer), meta lmarda tkun avvanzata.
English: As the company has supplied the additional information necessary, the authorisation has been switched from conditional to full approval.
Maltese: Peress li l-kumpanija forniet l-informazzjoni addizzjonali meħtieġa, lawtorizzazzjoni nqalbet minn kondizzjonali għal approvazzjoni sħiħa.
English: For the full list of side effects and restrictions with Zykadia, see the package leaflet.
Maltese: Għal-lista sħiħa tal-effetti sekondarji u restrizzjonijiet bi Zykadia, ara l-fuljett ta' tagħrif.
English: Patients given Zykadia lived for an average of 16.6 months without their disease getting worse compared with 8.1 months in patients given standard chemotherapy.
Maltese: Il-pazjenti li ngħataw Zykadia għexu medja ta' 16.6 xhur mingħajr ma l-marda tagħhom qalbet għall-agħar, meta mqabbel ma' 8.1 xhur f'pazjenti li ngħataw kimoterapija standard.
English: Results showed that patients given Zykadia lived for an average of 5.4 months without their disease getting worse (progression-free survival) compared with 1.6 months in patients given standard chemotherapy.
Maltese: Ir-riżultati wrew li l-pazjenti li ngħataw Zykadia għexu għal medja ta' 5.4 xhur mingħajr ma lmarda tagħhom qalbet għall-agħar (sopravivenza mingħajr progressjoni) meta mqabbel ma' 1.6 xhur f'pazjenti li ngħataw kimoterapija standard.
English: The recommended dose is 450 mg (3 capsules) once a day taken with food at the same time each day.
Maltese: Id-doża rakkomandata hija 450 mg (3 kapsuli) darba kuljum mal-ikel fl-istess ħin kull jum.
English: Regarding safety, the adverse effects with Zykadia generally appeared manageable.
Maltese: Fir-rigward tas-sigurtà, l-effetti avversi b'Zykardia ġeneralment dehru li jiġu mmaniġġjati.
English: The presence of genetic defects affecting ALK (‘ALK-positive' status) has to be confirmed in advance by appropriate methods.
Maltese: Il-preżenza ta' difetti ġenetiċi li jaffettwaw l-ALK (status “pożittiv għall-ALK”) għandha tiġi kkonfermata bil-quddiem permezz ta' metodi adegwati.
English: The average length of response was 8.3 months.
Maltese: It-tul medju tar-rispons kien ta' 8.3 xhur.
English: The active substance in Zykadia, ceritinib, works by blocking the activity of ALK, thereby reducing the growth and spread of the cancer.
Maltese: Is-sustanza attiva f'Zykadia, ceritinib, taħdem billi timblokka l-attività ta' ALK, b'hekk jitnaqqas it-tkabbir u t-tixrid tal-kanċer.
English: In patients with ALK-positive NSCLC, an abnormal form of ALK is produced that stimulates the cancer cells to divide and grow in an uncontrolled fashion.
Maltese: F'pazjenti b'NSCLC pożittiv għall-ALK, tiġi prodotta forma anormali ta' ALK li tistimula liċ-ċelloli tal-kanċer biex jinqasmu u jikbru b'mod mhux ikkontrollat.
English: It is only used if the NSCLC is ‘ALKpositive', which means that the cancer cells have certain defects affecting the gene responsible for a protein called ALK (anaplastic lymphoma kinase).
Maltese: Dan jintuża biss jekk l-NSCLC ikun “pożittiv għall-ALK”, li jfisser li ċ-ċelloli talkanċer ikun fihom ċerti difetti li jaffettwaw lill-ġene responsabbli minn proteina msejħa ALK (kinasi tallimfoma anaplastika).
English: How is Zykadia used?
Maltese: Kif jintuża Zykadia?
English: Zykadia has been shown to be effective at treating advanced, ALK-positive NSCLC in three main studies in patients whose disease progressed despite previous treatment with the medicine crizotinib:
Maltese: Zykadia ntwera li hu effettiv fil-kura ta' NSCLS avvanzat pożittiv għall-ALK fi tliet studji ewlenin f'pazjenti li l-marda tagħhom ipprogressat minkejja kura preċedenti bil-mediċina crizotinib:
English: Response to treatment was assessed using body scans and standardised criteria used for solid tumours, with complete response being when the patient had no remaining signs of the cancer.
Maltese: Ir-rispons għall-kura ġie vvalutat permezz ta' skenns tal-ġisem u kriterji standardizzati użati għal tumuri solidi, b'rispons komplet li jkun meta l-pazjent ma kien baqagħlu l-ebda sinjal tal-kanċer.
English: Sevohale1 (sevoflurane)
Maltese: Sevohale1 (sevofluran)
English: Further information on Sevohale can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: Sevohale is a ‘generic medicine'.
Maltese: Sevohale huwa ‘mediċina ġenerika'.
English: Sevocalm received a marketing authorisation valid throughout the EU on 21/06/2016.
Maltese: Sevocalm ingħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fil-21/06/2016.
English: 1 Previously known as Sevocalm
Maltese: 1 Preċedentement magħruf bħala Sevocalm
English: Other information about Sevohale
Maltese: Informazzjoni oħra dwar Sevohale
English: It contains the active substance sevoflurane, a chemical which is a liquid at room temperature, but when heated becomes a gas (vaporises).
Maltese: Dan fih is-sustanza attiva sevofluran, sustanza kimika li hija likwida f'temperatura ambjentali, iżda li meta tissaħħan issir gass (tivvaporizza).
English: How has Sevohale been studied?
Maltese: Kif ġie studjat Sevohale?
English: The name of the medicine was changed to Sevohale on 29 July 2016.
Maltese: L-isem talmediċina nbidel għal Sevohale fid-29 ta' Lulju 2016.
English: This summary was last updated in March 2018.
Maltese: Dan is-sommarju ġie aġġornat l-aħħar fi 03-2018.
English: This means that Sevohale contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called SevoFlo.
Maltese: Dan ifisser li Sevohale fih l-istess sustanza attiva u jaħdem bl-istess mod ta' ‘mediċina ta' referenza' li diġà hija awtorizzata fl-Unjoni Europea (UE) li jisimha SevoFlo.
English: No additional studies were needed as Sevohale is a generic medicine that is given by inhalation and contains the same active substance as the reference medicine, SevoFlo.
Maltese: Ma kien meħtieġ l-ebda studju addizzjonali billi Sevohale huwa mediċina ġenerika mogħtija permezz ta' inalazzjoni u fih l-istess sustanza attiva bħal dik tal-mediċina ta' referenza, SevoFlo.
English: Sevohale is a general anaesthetic for dogs and cats.
Maltese: Sevohale huwa anestetiku ġenerali għall-klieb u l-qtates.
English: Because Sevohale is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Sevohale huwa mediċina ġenerika, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk talmediċina ta' referenza.
English: What are the benefits and risks of Sevohale?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Sevohale?
English: Sevohale is used to bring about and maintain general anaesthesia (loss of consciousness).
Maltese: Sevohale jintuża biex jibda u jżomm lanesteżija ġenerali (telf mis-sensi).
English: How is Sevohale used?
Maltese: Kif jaħdem Sevohale?
English: Why is Sevohale authorised in the EU?
Maltese: Għalfejn Sevohale huwa awtorizzat fl-UE?
English: The European Medicines Agency concluded that, in accordance with EU requirements, Sevohale has been shown to be comparable to SevoFlo.
Maltese: L-Aġenzija Ewropea għall-Mediċini kkonkludiet li, f'konformità mar-rekwiżiti tal-UE, Sevohale ntwera li huwa komparabbli ma' SevoFlo.
English: The precautions are the same as for the reference medicine since Sevohale is a generic medicine.
Maltese: Il-prekawzjonijiet huma bħal dawk tal-mediċina ta' referenza minħabba li Sevohale huwa mediċina ġenerika.
English: Safety information has been included in the summary of product characteristics and the package leaflet for Sevohale, including the appropriate precautions to be followed by healthcare professionals and animal owners or keepers.
Maltese: Fis-sommarju tal-karatteristiċi tal-prodott u l-fuljett ta' tagħrif ġiet inkluża informazzjoni rigward issigurtà għal Sevohale, inkluż il-prekawzjonijiet xierqa li għandhom ikunu segwiti mill-professjonisti filqasam tal-kura tas-saħħa u mis-sidien tal-annimali jew dawk li jieħdu ħsiebhom.
English: Sevohale is given using specialised anaesthetic equipment, usually in a carefully controlled mixture including oxygen.
Maltese: Informazzjoni dwar il-mediċina ta' referenza tinstab ukoll fis-sit elettroniku tal-Aġenzija.
English: For more information about using Sevohale, see the package leaflet or contact your veterinarian or pharmacist.
Maltese: Għal aktar informazzjoni dwar l-użu ta' Sevohale, aqra l-fuljett ta' tagħrif jew ikkuntattja lill-veterinarju jew lillispiżjar tiegħek.
English: ATCvet code: QI02AA04.
Maltese: QI02AA04.
English: 29, avenue Tony Garnier 69007 Lyon
Maltese: 29 avenue Tony Garnier 69007 Lyon France
English: BOEHRINGER INGELHEIM ANIMAL HEALTH Netherlands B.V. Houtribweg 39
Maltese: ANIMAL HEALTH Netherlands B.V. Houtribweg 39
English: Date of first authorisation: 15/07/2013 Date of last renewal: 14/06/2018
Maltese: Data tal-ewwel awtorizzazzjoni: 15/07/2013 Data tal-aħħar tiġdid: 14/06/2018
English: Sodium chloride Potassium dihydrogen phosphate Potassium chloride Disodium phosphate anhydrous Potassium hydroxide Water for injections.
Maltese: Sodium chloride Potassium dihydrogen phosphate Potassium chloride Disodium phosphate anhydrous Potassium hydroxide Ilma għal injezzjonijiet.
English: Mannide mono-oleate Polysorbate 80
Maltese: Paraffin, likwidu Mannide mono-oleate Polysorbate 80
English: 10 doses 25 doses 50 doses 100 doses 150 doses 10 x 10 doses 10 x 25 doses 10 x 50 doses 10 x 100 doses 10 x 150 doses
Maltese: 10 dożi 25 doża 50 doża 100 doża 150 doża 10 x 10 dożi 10 x 25 doża 10 x 50 doża 10 x 100 doża 10 x 150 doża
English: Onset of immunity:
Maltese: Bidu tal-immunità
English: Liquid paraffin 537 mg. White emulsion after shaking.
Maltese: Paraffin likwidu 537 mg.
English: 10 doses 25 doses
Maltese: 25 doża
English: Vaccination of cattle with strains O1 Manisa, O1 BFS, A22 Iraq, A24 Cruzeiro, A Turkey 14/98, Asia1 Shamir and SAT2 Saudi Arabia resulted in a reduction of clinical signs in animals exposed to infection.
Maltese: Tilqim ta' baqar bl-istrejns O1 Manisa, O1 BFS, A22Iraq, A24 Cruzeiro, A Turkey 14/98 Asia 1 Shamir u SAT2 Għarabja Sawdita wassal għal tnaqqis fis-sinjali kliniċi f'annimali esposti għallinfezzjoni.
English: * PD50 - 50% protective dose in cattle as described in Ph. Eur.
Maltese: *PD50: 50% doża protettiva fil-baqar kif deskritta fil-monografu Ph.Eur. 0063.
English: O1 Manisa ................................................................................................................................. ≥ 6 PD50* O1 BFS ....................................................................................................................................... ≥ 6 PD50* O Taiwan 3/97 ........................................................................................................................... ≥ 6 PD50* A22 Iraq ..................................................................................................................................... ≥ 6 PD50* A24 Cruzeiro ............................................................................................................................. ≥ 6 PD50* A Turkey 14/98 ......................................................................................................................... ≥ 6 PD50* Asia 1 Shamir ............................................................................................................................. ≥ 6 PD50* SAT2 Saudi Arabia ................................................................................................................... ≥ 6 PD50*
Maltese: ............... ≥ 6 PD50* A22 Iraq ..................................................................................................................................... ≥ 6 PD50* A24 Cruzeiro ............................................................................................................................. ≥ 6 PD50* A Turkey 14/98 ..................................................................................................................
English: The frequency of adverse reactions is defined using the following convention: - very common (more than 1 in 10 animals treated displaying adverse reaction(s)) - common (more than 1 but less than 10 animals in 100 animals treated) - uncommon (more than 1 but less than 10 animals in 1,000 animals treated ) - rare (more than 1 but less than 10 animals in 10,000 animals treated) - very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
Maltese: Il-frekwenza ta' effetti mhux mixtieqa hija definita skont din il-konvenzjoni: - komuni ħafna (aktar minn wieħed f'10 annimali li juru effett(i) mhux mixtieq(a) matul il perjodu ta' kura waħda) - komuni (aktar minn wieħed iżda inqas minn 10 annimali f'100 annimal) - mhux komuni (aktar minn wieħed iżda inqas minn10 annimali f'1,000 annimal) - rari (aktar minn wieħed iżda inqas minn10 annimali f'10,000 annimal) - rari ħafna (inqas minn annimal wieħed f'10,000 annimal, inklużi rapporti iżolati).
English: 50 doses 100 doses 150 doses
Maltese: 150 doża
English: Lot {number}
Maltese: Baqar u nagħaġ:
English: Pigs: IM.
Maltese: IM.
English: Each dose of 2 ml of emulsion contains:
Maltese: U INGREDJENT(I) OĦRA Kull doża ta' 2 ml ta' emulsjoni fiha:
English: Inactivated foot-and-mouth disease antigens are purified and do not contain sufficient amounts of non-structural proteins (NSP) to induce an antibody response following administration of a trivalent vaccine containing an amount of antigen corresponding with at least 15 PD50 per strain per dose of 2 ml.
Maltese: L-antiġeni inattivati tal-marda tal-ilsien u d-dwiefer huma ppurifikati u ma fihomx ammonti suffiċjenti ta' non-structural proteins (NSP) biex jinduċi rispons tal-antikorp wara l-għotja ta' vaċċin trivalent li fih ammont ta' antiġen li jikkorispondi ma' mill-inqas 15 PD50 għal kull strejn għal kull doża ta' 2 ml.
English: No antibodies to NSP were detected using the PrioCHECK FMDV NS test kit:
Maltese: L-ebda antikorp għal NSP ma ġie misjub meta ntuża t-test kit PrioCHECK
English: Pharmaceutical group: inactivated viral vaccine, foot-and-mouth disease virus.
Maltese: Grupp farmaċewtiku: vaċċin virali inattivat.
English: Vaccination of pigs with strains O Taiwan 3/97 and A22 Iraq resulted in a reduction of clinical signs in animals exposed to infection.
Maltese: Tilqim ta' ħnieżer bl-istrejns O Taiwan 3/97 u A22 Iraq wassal għal tnaqqis fis-sinjali kliniċi f'annimali esposti għall-infezzjoni.
English: A slight increase of rectal temperature of up to 1.2 °C for 4 days post-vaccination with no other generalised clinical signs is commonly observed.
Maltese: Ġiet osservata b'mod komuni żieda ħafifa fit-temperatura tar-rektum sa' 1.2° għal 4 ijiem wara ttilqim bl-ebda sinjali oħra kliniċi ġeneralizzati.
English: Cardboard box with 1 bottle of 10, 25, 50, 100 or 150 doses Cardboard box with 10 bottles of 10, 25, 50, 100 or 150 doses
Maltese: Kaxxa tal-kartun b'10 fliexken ta' 10, 25, 50, 100 jew 150 doża.
English: The number and type of strains included in the final product will be adapted to the current epidemiological situation at the time of formulation of the final product and will be shown on the label.
Maltese: In-numru u t-tip ta' strejns inklużi fil-prodott finali jiġu adattati għas-sitwazzjoni epidemjoloġika attwali fil-waqt tal-formulazzjoni tal-prodott finali u jkunu jidhru fuq it-tikketta.
English: FMD antigen ≥ 6 PD50 per strain
Maltese: TAS-SUSTANZA(I) ATTIVA(I) Antigen tal-FMD ≥ 6 PD50 għal kull strejn
English: Zero days.
Maltese: 100 doża
English: Inactivated FMD antigen, ≥ 6 cattle PD50 per strain.
Maltese: DIKJARAZZJONI TAS-SUSTANZA ATTIVA U SUSTANZI OĦRA Antiġen inattivat tal-FMD,˃ 6 PD50 fil-baqar għal kull strejn
English: - in cattle following administration of a double dose followed by a single dose 7 weeks later and a third vaccination with a single dose 13 weeks after the second dose, - in sheep following administration of a double dose followed by a single dose 5 weeks later and a third vaccination with a single dose 7 weeks after the second dose, - in pigs following administration of a double dose followed by a single dose 3 weeks later and a third vaccination with a single dose 7 weeks after the second dose.
Maltese: - fil-baqar wara l-għotja ta' doża doppja segwita minn doża waħda 7 ġimgħat wara u t-tielet tilqima b'doża waħda 13-il ġimgħa wara t-tieni doża, - fin-nagħaġ wara l-għotja ta' doża doppja segwita minn doża waħda 5 ġimgħat wara u t-tielet tilqima b'doża waħda 7 ġimgħat wara t-tieni doża, - fil-ħnieżer wara l-għotja ta' doża doppja segwita minn doża waħda 3 ġimgħat wara u t-tielet tilqima b'doża waħda 7 ġimgħat wara t-tieni doża.
English: Swellings (diameter of up to 12 cm in ruminants and 4 cm in pigs) occurred very commonly in most animals after administration of a dose of vaccine.
Maltese: Kien hemm nefħa (dijametru sa' 12 cm f'annimali li jixtarru u 4 cm fil-ħnieżer) b'mod komuni ħafna fil-maġġor parti tal-annimali.
English: ADVICE ON CORRECT ADMINISTRATION
Maltese: U MANIFATTUR RESPONSABBLI
English: Any person intending to manufacture, import, possess, sell, supply and use this veterinary medicinal product must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.
Maltese: Kull persuna li turi l-intenzjoni li timmanifattura, timporta, tippossjedi, tbigħ, tipprovdi u tuża dan ilprodott veterinarju mediċinali għandha l-ewwel tikkonsulta mal-Awtorità Kompetenti tal-Istat Membru dwar il-programmi ta' tilqim kurrenti peress li dawn l-attivitajiet jistgħu jkunu projbiti fi Stat Membru fit-territorju kollu tiegħu jew f'parti minnu taħt leġislazzjoni nazzjonali.
English: Manufacturer responsible for batch release:
Maltese: METODU U MOD(I) TA' AMMINISTRAZZJONI Baqar u nagħaġ:
English: Paraffin, liquid
Maltese: ANNESS I KARATTERISTIĊI
English: Following repeated administration at short intervals, the intensity of these reactions may be increased.
Maltese: Wara l-għotja ripetuta f'intervalli qsar, l-intensità ta' dawn l-effetti tista' tiżdied.
English: In trials the following has been demonstrated:
Maltese: Detentur tal-awtorizzazzjoni għat-tqegħid fis-suq:
English: AFTOVAXPUR DOE Emulsion for injection for cattle, sheep and pigs
Maltese: VETERINARJU AFTOVAXPUR DOE emulsjoni għal injezzjoni għal baqar, nagħaġ u ħnieżer
English: AFTOVAXPUR DOE emulsion for injection for cattle, sheep and pigs
Maltese: VETERINARJU AFTOVAXPUR DOE emulsjoni għal injezzjoni għal baqar, nagħaġ, u ħnieżer.
English: Do not mix with any other veterinary medicinal product.
Maltese: Tużax flimkien ma' prodotti mediċinali veterinarji oħra.
English: Polypropylene bottle with a nitrile elastomer closure and sealed with an aluminium cap.
Maltese: Flixkun tal-polypropylene bit-tapp tan-nitrile elastomer u ssiġillat b'tapp tal-aluminju.
English: INDICATIONS
Maltese: TAMMINISTRA
English: Emulsion for injection.
Maltese: GĦAMLA FARMAĊEWTIKA Emulsjoni għal injezzjoni
English: Shelf life of the veterinary medicinal product containing strain Asia1 Shamir as packaged for sale: 2 months.
Maltese: Żmien kemm idum tajjeb il-prodott mediċinali veterinarju li fih l-istrejn Asia 1 Shamir kif ippakkjat għallbejgħ: xahrejn.
English: Disposal: read package leaflet.
Maltese: Ripetizzjoni tal-vaċċinazzjoni: kull sitt xhur.
English: Active immunisation of cattle, sheep and pigs from 2 weeks of age against foot-and-mouth disease to reduce clinical signs.
Maltese: Immunizzazzjoni attiva tal-baqar, nagħaġ u ħnieżer, 'il fuq minn ġimagħtejn kontra l-marda tal-ilsien u d-dwiefer biex tnaqqas sinjali kliniċi.
English: Shelf life of the veterinary medicinal product not containing strain Asia1 Shamir as packaged for sale: 6 months.
Maltese: Żmien kemm idum tajjeb il-prodott mediċinali veterinarju li ma fihx l-istrejn Asia 1 Shamir kif ippakkjat għall-bejgħ: 6 xhur
English: Apply usual aseptic procedures.
Maltese: Applika l-proċeduri asettiċi tas-soltu.
English: Liquid paraffin ............................................................................................................................. 537 mg.
Maltese: Paraffin likwidu ............................................................................................................................. 537 mg
English: Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given.
Maltese: In-numru u t-tip ta' strejns inklużi fil-prodott finali għandhom jiġu adattati għas-sitwazzjoni epidemjoloġika attwali f'dak il-waqt li jkun formulat il-prodott finali u jiġu murija fuq it-tikketta.
English: Vaccination of pigs with strain Asia1 Shamir resulted in a reduction of clinical signs and virus shedding in animals exposed to infection.
Maltese: Tilqim ta' ħnieżer bl-istrejn Asia 1 Shamir wassal għal tnaqqis fis-sinjali kliniċi u tixrid tal-vajrus f'annimali esposti għall-infezzjoni.
English: If pain persists for more than 12 hours after medical examination, seek medical advice again.
Maltese: Jekk l-uġigħ idum għal aktar minn tnax-il siegħa, wara l-eżami mediku, erġa' ħu parir mediku .
English: (*) equivalent to titre prior to inactivation (log 10)
Maltese: (*) ekwivalenti għal titrazzjoni qabel ma jiġi inattivat (log 10)
English: Packaging
Maltese: Imballaġġ
English: Str. Cuza - Vodă nr. 99
Maltese: Cuza - Vodă nr. 99
English: Av. António Augusto de Aguiar, 128
Maltese: António Augusto de Aguiar, 128
English: Str. Livezeni nr. 7A 540472 Târgu Mureş România
Maltese: Livezeni nr. 7A 540472 Târgu Mureş România
English: Medica AD Industrial area Sandanski 2800 Bulgaria
Maltese: Medica AD Industrial area Sandanski 2800
English: 6, rue de la Rochefoucauld 16000 Angoulême France
Maltese: 6, rue de la Rochefoucauld 16000
English: Edifício Atlas II, Av. José Gomes Ferreira, N.º 113º, Sala 31 - Miraflores 1495-139 Algés Portugal
Maltese: José Gomes Ferreira, N.º 113º, Sala 31 - Miraflores 1495-139 Algés Portugal
English: Sandoz Hungária Kft. 1114 Budapest Bartók Béla út 43-47.
Maltese: Sandoz Hungária Kft. 1114 Budapest Bartók Béla út 43-47. Magyarország Hungary
English: Servier Austria GmbH Mariahilfer Straße 20/5 Vienna 1070
Maltese: Servier Austria GmbH Mariahilfer Straße 20/5
English: Ostrzykowizna 14A 05-170 Zakroczym Poland
Maltese: Przedsiębiorstwo Farmaceutyczne LEK-AM Sp. z o.o. Ostrzykowizna 14A 05-170 Zakroczym Poland
English: RATIOPHARM ESPAÑA, S.A. Avda.
Maltese: ESPAÑA, S.A. Avda.